LONGEVA.

Liraglutide: adverse events and evidence limits

A 56-week subcutaneous liraglutide trial enrolled adults without type 2 diabetes with obesity, or overweight plus hypertension or dyslipidemia. Common events were mild or moderate nausea and diarrhea; serious events occurred in both arms. [1]

The inspected abstract does not establish each event’s causality or a particular catalog reagent’s safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
NauseaAdults without type 2 diabetes with obesity, or overweight plus hypertension or dyslipidemia; subcutaneous liraglutide, 56 weeksAmong the most commonly described events, mild or moderate; no percentage given in the abstract[1]
DiarrheaThe same participantsAmong the most commonly described events, mild or moderate; no percentage given in the abstract[1]
Serious eventsThe same participantsOccurred in both arms of the trial; no frequency given in the abstract[1]

References

  1. Xavier Pi-Sunyer et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management https://doi.org/10.1056/NEJMoa1411892.